In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
PUMP-2 trial combined FUDR via HAIP with gemcitabine and cisplatin, no immunotherapy was on the protocol.
Answer from: Medical Oncologist at Academic Institution
While HAIP is considered promising (again - 20 years later), no appropriate phase III trial has shown benefit in any diagnosis. Since phase III trials support immunotherapy, that is preferred.
Answer from: Medical Oncologist at Academic Institution
Thank you for the question. I agree that the HAIP can be an effective option for carefully selected patients ineligible for resection in the hands of experts experienced with HAIP- and has offered improvements in PFS & OS. However, to date, published data has only been in combination with cytoto...
Answer from: Medical Oncologist at Community Practice
Based on the concept that hepatic metastases derive most of their blood supply from the hepatic artery as opposed to venous system hepatic arterial infusion (HAI) has been evaluated in the past for mostly colorectal cancer patients with hepatic metastases. (Copur et al., PMID 11331319, Kemeny et al....
Comments
Medical Oncologist at Rutgers Cancer Institute of New Jersey The only benefit of HAIP is to deliver a higher co...